title: Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease.
abstract: OBJECTIVE
  To systematically study potential adverse events associated with the use of intraocular bevacizumab at a single medical center.
  
  
  METHODS
  Retrospective study of all consecutive patients receiving intraocular bevacizumab injections at the Stanford University Department of Ophthalmology between November 15, 2005 and July 14, 2006. Bevacizumab was given for exudative age-related macular degeneration, retinal vascular occlusion, diabetic macular edema, neovascular glaucoma, and five other indications.
  
  
  RESULTS
  We analyzed medical records of 186 subjects (203 eyes) who received a total of 578 injections of 1.25 mg of bevacizumab. The average follow-up was approximately 6 months. Five eyes with exudative age-related macular degeneration developed retinal pigment epithelial (RPE) tears, all with preexisting RPE detachments. These five eyes represented 2.9% of all age-related macular degeneration eyes treated and 7% of the age-related macular degeneration eyes with preexisting RPE detachments at initiation of treatment. Other adverse events were rare and included retinal ischemia, subretinal hemorrhage, vitreous hemorrhage, ocular irritation or pain, worsened hypertension, and headache. No death or thromboembolic events were observed.
  
  
  CONCLUSIONS
  Intraocular bevacizumab appears to be well tolerated for the treatment of a variety of retinal and choroidal vascular diseases. RPE tears may occur when treating choroidal neovascularization, particularly in patients with preexisting RPE detachment.
authors.affiliation: Department of Ophthalmology, Stanford University School of Medicine, Stanford, California 94025, USA.
authors.forename: Lisa J
authors.initials: LJ
authors.lastname: Wong
authors.forename: Rajen U
authors.initials: RU
authors.lastname: Desai
authors.forename: Atul
authors.initials: A
authors.lastname: Jain
authors.forename: David
authors.initials: D
authors.lastname: Feliciano
authors.forename: Darius M
authors.initials: DM
authors.lastname: Moshfeghi
authors.forename: Steven R
authors.initials: SR
authors.lastname: Sanislo
authors.forename: Mark S
authors.initials: MS
authors.lastname: Blumenkranz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015862:Choroid Diseases / Q000188:drug therapy*; D020256:Choroidal Neovascularization / Q000150:complications / Q000188:drug therapy; D005128:Eye Diseases / Q000139:chemically induced; D005260:Female; D005500:Follow-Up Studies; D006261:Headache / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007267:Injections; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy; D008297:Male; D012163:Retinal Detachment / Q000150:complications; D012164:Retinal Diseases / Q000188:drug therapy*; D012167:Retinal Perforations / Q000139:chemically induced; D055213:Retinal Pigment Epithelium / Q000187:drug effects; D012171:Retinal Vessels / Q000187:drug effects*; D012189:Retrospective Studies; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab